Liability Related to Sale of Future Royalties (Tables)

6 Months Ended

Jun. 30, 2024

The following table sets forth information on our liability related to sale of future royalties (in thousands):

Proceeds from sale of future royalties in January 2023	$	500,000
Issuance costs related to sale of future royalties		(10,434	)
Royalty payments to Royalty Pharma		(44,628	)
Interest expense related to sale of future royalties		68,238
Amortization of issuance costs related to sale of future royalties		560
Net liability related to sale of future royalties as of December 31, 2023		513,736
Royalty payments to Royalty Pharma		(16,236	)
Interest expense related to sale of future royalties		35,949
Amortization of issuance costs related to sale of future royalties		305
Net liability related to sale of future royalties as of June 30, 2024	$	533,754